Cumulus Neuroscience
Tracked across 2 events · 12 articles · First seen May 28, 2026 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Cumulus Neuroscience is the developer of the NeuLogiq platform and the sponsor of the CNS-102 study. The publication in Scientific Reports validates its technology, potentially enhancing its reputation and commercial opportunities in CNS clinical trials.
Aug 18, 2026 · 6 articles
Tech
Impact: Cumulus Neuroscience's NeuLogiq Platform was instrumental in confirming the safety and cognitive function of zalsupindole, validating its platform's utility in neuropsychiatry clinical trials and potentially increasing its partnerships.
May 28, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Cumulus Neuroscience live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard